Reading this board just for a few minutes I almost gave up: what a bunch of xxx!
Retail, retail, and retail what can I say about you, assuming you are innocent and genuine, not part of Fudster gang
Have yet to completed your Sherlock Holmes's work on whether the trial has failed or not or whether the trial will fail or not?
Haven't turned this century old page yet? Then, can you please draw a curve using the blinded, blended updated data of DCVax-L trial and the curves of the other three best comparable, contemporaneous trials who received standard of care therapy only. can you see DCVax-L's primary endpoint is met with ss?
Do you forget DCVax-L is also safe?
In the support of the effectiveness expressed by the ss met primary endpoint, if that's not enough, then there are other five secondary endpoints individually or in combination if also met ss, will you still have any doubt DCVax-L is both safe and effective?
And after you have seen DCVax-L as a whole will have triple or quadruple more patients living over five years compared to the SOC, will you still doubt DCVax-L is effective?
In effect, even without the support of any secondary endpoints being met ss which will be highly unlikely, there have been a large number of various data points from peripheral blood samples, etc collected during the trial process from al patients, which can point to the immunogenicity differences in favor of the treatment arm patents.
The question now you should ask is how successful the trial will be. If you still have not grasped this very basics on what we are as of today as an investor, really I have no further words on you.
Let me repeat buying any shares below $2 is no brainier!
